See more : Prozone Intu Properties Limited (PROZONINTU.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Freeline Therapeutics Holdings plc (FRLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Freeline Therapeutics Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Cognetivity Neurosciences Ltd. (CGNSF) Income Statement Analysis – Financial Results
- Schneider Electric S.E. (SBGSF) Income Statement Analysis – Financial Results
- Nazara Technologies Limited (NAZARA.NS) Income Statement Analysis – Financial Results
- AGEHA Inc. (9330.T) Income Statement Analysis – Financial Results
- Periphas Capital Partnering Cor (PCPC-WT) Income Statement Analysis – Financial Results
Freeline Therapeutics Holdings plc (FRLN)
About Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 2.39M | 1.93M | 1.55M | 0.00 |
| Gross Profit | -1.74M | -2.39M | -1.93M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.20M | 95.43M | 76.15M | 47.04M | 34.19M |
| General & Administrative | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Other Expenses | -1.57M | -2.09M | -15.27M | -10.60M | -390.00K |
| Operating Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Cost & Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Interest Income | 904.00K | 403.95K | 275.00K | 74.31K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 151.00K |
| Depreciation & Amortization | 1.27M | 9.24M | 17.18M | 12.14M | 970.00K |
| EBITDA | -97.17M | -133.14M | -85.27M | -51.51M | -32.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -98.45M | -142.38M | -102.45M | -63.64M | -40.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.84M | 2.33M | 6.26M | 9.88M | -470.80K |
| Income Before Tax | -88.60M | -140.05M | -96.19M | -53.77M | -33.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 368.00K | 342.00K | 129.00K | 141.00K | 27.00K |
| Net Income | -88.97M | -140.39M | -96.32M | -53.91M | -33.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| EPS Diluted | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| Weighted Avg Shares Out | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
| Weighted Avg Shares Out (Dil) | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Acquisition of Freeline by Syncona Becomes Effective
Freeline Shareholders Approve Acquisition by Syncona
FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
FREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline Therapeutics Holdings plc - FRLN
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
FRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to Shareholders
Syncona to Acquire Freeline Therapeutics
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
Source: https://incomestatements.info
Category: Stock Reports